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Background: The safety of beta-blockers as a heart rate-limiting drug (HRLD) in patients with acute respiratory
failure (ARF) due to chronic obstructive lung disease (COPD) has not been properly assessed in the intensive care
unit (ICU) setting. This study aims to compare the use of beta-blocker drugs relative to non-beta-blocker ones in
COPD patients with ARF due to heart rate-limiting with respect to length of ICU stay and mortality.
Methods: We performed a retrospective (January 2011-December 2012) case-control study in a level III ICU in a
teaching hospital. It was carried out in a closed ICU by the same intensivists. All COPD patients with ARF who were
treated with beta-blockers (case group) and non-beta-blocker HRLDs (control group) were included. Their demographics,
reason for HRLD, cause of ARF, comorbidities, ICU data including acute physiology and chronic health evaluation (APACHE
II) score, type of ventilation, heart rate, and lengths of ICU and hospital stays were collected. The mortality rates in the ICU,
the hospital, and over 30 days were also recorded.
Results: We enrolled 188 patients (46 female, n = 74 and n = 114 for the case and control groups, respectively). Reasons
for HRLD (case and control group, respectively) were atrial fibrillation (AF, 23% and 50%), and supraventricular tachycardia
(SVT, 41.9% and 54.4%). Patients’ characteristics, APACHE II score, heart rate, duration and type of ventilation, and median
length of ICU-hospital stay were similar between the groups. The mortality outcomes in the ICU, hospital, and 30 days
after discharge in the case and control groups were 17.6% versus 15.8% (p > 0.75); 18.9% versus 19.3% (p > 0.95) and 20%
versus 11% (p > 0.47), respectively.
Conclusions: Our results suggest that beta-blocker use for heart rate control in COPD patients with ARF is associated with
similar ICU stay length and mortality compared with COPD patients treated with other HRLDs.
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The majority of patients with chronic obstructive pul-
monary disease (COPD) have chronic heart failure
(CHF) or coronary artery disease (CAD) [1]. The risk
of cardiac arrhythmia is increased during acute exacer-
bations of COPD [1]. Atrial fibrillation (AF) is fre-
quently observed in elderly COPD patients [2], and* Correspondence: zuhalkarakurt@hotmail.com
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stated.cardiac arrhythmias are a significant cause of mortality in
these patients [3]. COPD patients with CAD generally
have elevated heart rates, and beta-adrenergic receptor an-
tagonists (beta-blockers) are known to improve the sur-
vival of patients with CHF or CAD [4,5]. Previous studies
have shown that patients with CAD and coexisting COPD
generally failed to receive optimal therapy or appropriate
drug dosages for HR reduction. In a recent study, 54% of
patients suffered from heart failure in a population with
CAD and COPD, and only 52.8% of these patients were
receiving beta-blocker therapy. In addition, in the majority
of these patients the daily dosages of beta-blockers wereLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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tation to prescribe them due to possible adverse pulmonary
effects [6]. The current medical treatment approach for
COPD exacerbation is the administration of short-acting
bronchodilators (ß2-agonists), with or without anticholiner-
gic compounds and corticosteroids [7]. COPD patients with
arrhythmias require complex treatment strategies. Studies
comparing the side effects of beta-blockers have yielded
mixed results in patients with arrhythmias and myocardial
infarction (MI) [8-11].
There are limited data about patients with acute respira-
tory failure (ARF) in the intensive care unit (ICU) that
demonstrated the safety of beta-blockers in COPD pa-
tients with arrhythmias. In this study, we compared the
outcomes of COPD patients with ARF who received beta-
blockers versus other medications for heart rate control.
We hypothesized that the use of beta-blockers as a heart
rate-limiting drug (HRLD) in COPD patients with ARF
would achieve similar outcomes with respect to mortality
and length of ICU stay as other non-beta-blocker drugs.Methods
We performed a retrospective case–control study in the
ICU of a teaching hospital for chest diseases between
January 2011 and December 2012. The 22-bed ICU was
classified as level III and was operated as a closed unit by
eight pulmonologist-intensivist specialists 24 hours/day
and 7 days/week. The majority of ARF patients admitted
to the ICU had COPD. This study was approved by the
local ethical committee of the government teaching hos-
pital (Sureyyapasa Chest Diseases and Thoracic Surgery
Teaching Hospital-Istanbul-Turkey).Patients
All consecutive patients with previously diagnosed COPD
who were admitted to the ICU due to ARF during the
study period were evaluated. COPD diagnoses were estab-
lished by a physician based on airflow obstruction on spir-
ometry, defined as a forced expiratory volume in 1 second
(FEV1) and forced vital capacity ratio of 70% or less. We
searched the electronic database system and International
Classification of Disease (ICD)-10 coding system and re-
corded “J 44” as COPD. Patients were enrolled in the
study if they had been treated with HRLDs at any time
during their ICU stay. Patients with asthma or previous
use with diltiazem were excluded from the study, as
were those who had been in the ICU for less than 24
hours. The patients were divided into two groups ac-
cording to their HRLD treatment: beta-blocker (case
group) and non-beta-blocker (control group). The
HRLDs administered in the case group included meto-
prolol, bisoprolol, and carvedilol, and those given to thecontrol group were diltiazem, digoxin, amiodarone, or
any combination of these.
Data
The presence of comorbidities, including diabetes melli-
tus (E 10–11), ischemic heart disease (I 25), and atrial
fibrillation (I 48), was determined by the ICD coding in
our teaching hospital database. Previous HRLD use was
also recorded at the time of ICU admission. Any previ-
ous hospital admissions were recorded as emergency ser-
vice, hospital ward, and other ICU. Body mass index (BMI),
reason for HRLD use, causes of ARF, acute physiological
and chronic health evaluation (APACHE II score) [12], ap-
plication and duration of noninvasive (NIV) or invasive
mechanical ventilation (IMV), heart rate, C-reactive protein
(CRP) level at ICU admission and the peak value during
ICU stay, biochemistry values, complete blood counts, spu-
tum/tracheal aspirate/bronchial lavage cultures, lengths of
ICU and hospital stays, and mortality in the ICU and hos-
pital were recorded from the patients’ files. Mortality within
30 days of hospital discharge was recorded from the online
deceased declaration system to assess short-term mortality.
Definitions
ARF
Patients were divided into three groups according to their
arterial blood gas (ABG) results on admission to the ICU.
“Hypoxic ARF” was defined if partial arterial oxygen
pressure in inspired fractionated oxygen (PaO2/FiO2) was
< 300 and partial arterial carbon dioxide pressure (PaCO2)
was < 45 mmHg. “Hypercapnic and hypoxemic ARF” was
defined as PaCO2 > 45 mmHg and PaO2/FiO2 < 300, and
“hypercapnicARF” was PaCO2 > 45 mmHg and PaO2/
FiO2 > 300 [13,14].
Sepsis
The presence of sepsis was defined as the presence of in-
fection together with systemic inflammatory response syn-
drome [15,16]. Patients who were unresponsive to fluid
resuscitation and required vasopressor agents were de-
fined as being in septic shock [16].
Treatment
HRLDs used in the ICU were recorded in six major indica-
tion subgroups: 1) AF [17], 2) supraventricular tachycardia
(SVT) [18], 3) ventricular tachyarrhythmia (VT), 4) con-
gestive heart failure CHF [19], 5) hypertension (HT) [20],
and 6) suspicion of MI. These drugs were administered or-
ally or via intravenous (IV) injection or infusion. The drugs
and doses for CHF were as follows: metoprolol (12.5/25 mg
once daily [o.d.], starting dose targeting 200 mg o.d.) with
bisoprolol (1.25 mg o.d., starting dose targeting 10 mg o.d),
and carvedilol (3.125 mg, twice daily, starting dose targeting
25-50 mg), or digoxin (0.25 mg o.d.) [19]. The drug doses
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2 minutes, maximum 3 doses, oral maintenance dose 100-
200 mg, o.d.), bisoprolol (2.5-10 mg, o.d.), carvedilol (3.125-
25 mg, twice daily), diltiazem (60 mg twice daily to 360 mg
o.d.), digoxin (0.5-1 mg IV, then 0.125-0.5 mg o.d.), or ami-
odarone (5 mg/kg in 1 hour, 50 mg/hour maintenance; or
in oral form, 100-200 mg once daily) [17]. More than one
HRLDs (except beta-blockers) were defined as diltiazem
plus amiodarone and/or plus digoxin. While using these
drugs, the target heart rate was 80-100/minute [17]. No
HRLDs were administered if patients had septic shock. The
choice of HRLDs was totally dependent on intensivist staff
choice unless a known contraindication was present (e.g.,
diltiazem was not used in patients with lower ejection
fractions).
Treatment of COPD exacerbation
A short acting ß2 agonist (salbutamol, 100 mcg per
puff ) and ipratropium bromide (100 mcg/20 mcg per
puff ) were given every 2-4 hours (4 to 10 puffs) via a
metered dose inhaler chamber (Aerovent, Altech®, Altera
Firm, Izmir-Turkey) when the patients were under NIV or
IMV. A nebular form of salbutamol (2.5 mg/2.5 mL per
nebule) was given every 15 minutes to 4 hours, or ipratro-
pium bromide/salbutamol (0.5 mg/3.01 mg/2.5 mL per
nebule) was given every 2 to 4 hours for patients breathing
without mechanical ventilation support. Long-acting ß2-
agonists were not used in COPD patients with ARF in the
ICU [7,21]. The long-acting ß2-agonists, such as salme-
terol and formeterol, were not used during the ICU stay. A
systemic corticosteroid, prednisolone (30–40 mg per day),
was also administered [22]. Theophylline was not used in
eligible tachycardic COPD patients. Antibiotics were ad-
ministered according to recommended guidelines [22].
Mechanical ventilation
NIV was applied initially in the respiratory ward by a
specialized staff (nurse and specialist or resident) if pa-
tients were hemodynamically stable, cooperative, had
no organ failure except respiratory failure, their ABG
analysis revealed pH 7.28-7.34, PaCO2 = 45-90 mmHg,
PaO2/FiO2 > 200, and the Glasgow coma scale was > 13
due to hypercapnic confusion. ICU demand for patients
under NIV treatment in the ward was determined based
on cognitive function deterioration, lack of cooperation,
agitation, hemodynamically unstable conditions (e.g.,
hypotension, HT, tachycardia, arrhythmia) that needed
close monitoring, and deterioration of ABG values (in-
creased PaCO2, decreased PaO2, and decreased pH level).
NIV was provided in pressure assist-control mode with
ICU mechanical ventilators via a double-tube circuit with
a full-face mask [13]. Invasive mechanical ventilation was
applied in the presence of absolute or relative contraindi-
cations for NIV and in NIV failure [13]. Contraindicationsof NIV were defined as: 1) absolute, respiratory arrest and
unable to fit mask, and 2) relative, medically unstable
(hypotensive shock, uncontrolled cardiac ischemia or
arrhythmia, upper gastrointestinal bleeding), agitation,
uncooperativeness, inability to protect airway, impaired
swallowing, excessive secretions not managed by secretion
clearance techniques, multiple (two or more) organ fail-
ure, and recent upper airway or upper gastrointestinal sur-
gery [13,14]. The definition of NIV failure in hypercapnic
patients was no pH improvement, no change or a rise in
breathing frequency after 1–2 hours, and lack of cooper-
ation. For hypoxic COPD patients, failure was considered
as no, or a minimal, rise in PaO2/FiO2 after 1-2 hours
(< 200) [13]. The Richmond agitation sedation scale
(RASS) was used for infusion and assessment of the daily
need for sedation [23]. When patients met the previously
described criteria for weaning, they were extubated after
30 minutes of a successful T-piece trial [24]. After extuba-
tion, NIV was applied in cases of moderate respiratory
distress, if there were no contraindications [24].
Outcomes
The primary outcome was mortality (including hospital
and 30 days after hospital discharge), and the secondary
outcomes were NIV and IMV durations and the length
of ICU stay.
Statistical analysis
A descriptive analysis was used for patient demographics
and ICU data. Case and control groups were compared
with Mann Whitney U tests for non-parametric continu-
ous variables or Student’s t-tests for parametric continu-
ous variables. The chi-square test was employed for
dichotomous variables. Median and quartiles 1 and 3 were
used to describe non-parametric continuous variables, and
mean ± standard deviation (SD) was used for parametric
continuous variables. Count and percentage were used
when applicable. For predicting the mortality rates of ICU,
hospital, and 30 days after hospital discharge, logistic re-
gression analysis was applied using a model that included
HRLD type, APACHE II score on admission to the ICU,
age, reasons for ICU admission, NIV and IMV implications,
presence of septic shock, CRP level, and previous HRLD
use. P < 0.05 was accepted as statistically significant.
Results
During the study period, a total of 1,964 patients were ad-
mitted to the ICU, and 221 patients were using HRLDs.
After excluding 44 patients due to simultaneous beta-
blocker and diltiazem use, 188 patients were included in
the study. The patient enrollment flow chart is shown in
Figure 1.
Patient group demographics, comorbidities, reason for
ICU admission, microbiology results, and ICU data,
Patients in 2011-2012  n=1963 
Patients with COPD, n=731
Heart rate limiting drugs users n=221
Beta-Blocker user: n=74 Nonbeta-Blocker user: n=114
Patients enrolled into the study n=188
Patients stratified
Case Group Control Group
44 patients previous diltiazem & beta blocker  use
exclusion
Figure 1 Flow chart of patients enrollment.
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case group (using beta-blockers, n = 74) and the control
group (using non-beta-blockers, n = 114) were not signifi-
cantly different with regard to age, gender, body mass index,
comorbidities, reason for ICU admission, APACHE II
score, ABG on ICU admission, CRP values, or the presence
of sepsis and septic shock (Table 1). Previous use of HRLDs
before admission and in the ICU are shown in Table 2. Pre-
vious HRLD users in the case group were taking beta-
blockers (27/31), and most in the control group were previ-
ously prescribed diltiazem (37/57). During the ICU stay, the
case group received metoprolol, bisoprolol, or carvedilol,
and those in control group received diltiazem, digoxin, ami-
odarone, and more than one HRLD (except beta-blockers),
such as diltiazem plus amiodarone and/or plus digoxin
(Table 2). SVT was the most common reason for HRLD
use in both groups (Table 2). Heart rate and mean arterial
pressure values on admission to the ICU and the highest
values are also summarized in Table 2.
Types and duration of mechanical ventilation; lengths
of ICU and hospital stays; ICU, hospital, and 30-day
mortality after hospital discharge were compared be-
tween groups and shown in Table 3. The mortality rates
in both groups with respect to ICU, hospital, and within
30 days of hospital discharge were similar. NIV applica-
tion rate was significantly higher in beta-blocker users
(Table 3).
The initial mechanical ventilation (NIV or IMV) and
ICU/hospital mortality outcomes in both groups are
shown in Figure 2.
Eleven patients had do-not-intubate orders due to
family request underlying the terminal status of theCOPD (one patient had only nasal oxygen therapy, and
10 patients had only NIV treatment). In the only NIV-
applied group who received beta-blockers, we noted an
11.1% mortality rate versus 7.8% with non-beta-blockers.
However, all of the patients who died in the beta-blocker
group (n = 6, 100%) died with resistant organisms com-
pared to 60% of patients in the non-beta-blocker group
who died with a resistant pathogen (n = 3). Five out of
six (83.3%) patients in the beta-blocker group with failed
NIV and who were intubated for IMV had septic shock
due to a resistant pathogen.
A sub-analysis was performed in the case group to
evaluate mortality related to previous beta-blocker use.
There were 27 (36.5%) patients in the case group who
had previously used beta-blockers (Table 2). When we
compared them with patients who had only received
beta-blockers in the ICU (n = 47) we found that 96.2%
of the previous beta-blocker users required NIV versus
87.2% of the current beta-blocker users. Those who
required IMV on admission to ICU were 0% in the pre-
vious beta-blocker users versus 8.5% in the current
beta-blocker users, and those who required IMV after
initially receiving NIV were 30.7% in the previous beta-
blocker users versus 31.7% in the current beta-blocker
users. These results were similar between the two
groups. Mortality occurred in 4 of the 27 previous beta-
blocker users (1 was receiving only medical treatment, 2
were on NIV only, and 1 received IMV after NIV fail-
ure). Nine out of the 47 current beta-blocker users died
(1 had received only IMV, 2 received only NIV, and 5 re-
ceived IMV after NIV failure). All five patients in whom
NIV failed had a pan-resistant pathogen. CHF patients
Table 1 Patient characteristics for groups (case: beta-blockers, control: non-beta-blockers)
Case, n = 74 Control, n = 114 p value
Age, years, median (quartile 1–3) 71 (63–77) 71 (64–75) 0.82
Female/male 18/56 28/86 0.97
BMI, kg/m2, median (quartile 1–3) 23 (22–27) 24 (21–28) 0.82
Comorbidities, n (%) 69 (93.2) 100 (87.7) 0.22
AF, n (%) 56 (75.7) 80 (70.2) 0.41
Diabetes mellitus, n (%) 20 (27.0) 29 (25.4) 0.81
CAD, n (%) 12 (16.2) 14 (12.3) 0.45
Hypertension, n(%) 42(56.8) 73 (64) 0.32
Pre ICU location, n (%)
Emergency service 40 (54.1) 55 (48.2) 0.69
Hospital ward 31 (41.9) 55 (48.2)
Another ICU 3 (4.1) 4 (3.5)
Reason for ICU admission
COPD exacerbation 64 (86.5) 101 (88.6) 0.35
Pneumonia 8 (10.8) 6 (5.3)
Hemodynamic monitoring 0 (0) 3 (2.6)
Postoperative respiratory failure 0 (0) 1 (0.9)
Home ventilator evaluation 2 (2.7) 0 (0)
Sepsis, n (%) 50 (67.6) 76 (66.7) 0.90
Septic shock, n (%) 12 (16.2) 13 (11.4) 0.34
ICU admission APACHE-II value 19 (17–23) 20 (16–24) 0.88
ICU admission CRP mg/L 39 (14–91) 41 (14–125) 0.33
Peak of CRP mg/L median 64 (23–130) 110 (30–178) 0.08
Microbiologic culture, n (%) 51 (68.9) 67 (58.8) 0.16
Positive culture n (%) 18 (35.3) 27 (23.7) 0.58
Resistant pathogen, rate 14/18 23/27 0.43
Arterial blood gases analysis on admission ICU
pH, median (quartile 1–3) 7.28 (7.25-7.37) 7.32 (7.25-7.40) 0.08
PaCO2, mmHg, median (quartile 1–3) 72 (54–86) 73 (59–84) 0.78
PaO2/FiO2, median (quartile 1–3) 160 (130–211) 168 (116–230) 0.65
Type of acute respiratory failure, n(%)
PaO2/FiO2 <300 15 (20.3) 19 (16.7) 0.50
PaO2/FiO2 < 300 and PaCO2 > 45 mmHg 46 (62.2) 79 (69.3)
PaCO2 > 45 mmHg 13 (17.6) 16 (14.0)
AF, atrial fibrillation; APACHEII, acute physiologic and chronic health evaluation II; BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive
pulmonary disease; CRP, C-reactive protein; FiO2, fractionated inspired oxygen; ICU, intensive care unit, PaCO2, partial arterial carbon dioxide pressure; PaO2, partial
arterial oxygen pressure.
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ing the ICU stay (n = 11) had similar mortality rates
(14.8% versus 19.1%, p = 0.64).
During the study period, 363/1,963 patients died (19.5%)
in the ICU, and the mortality rate among the 731 patients
with COPD who were admitted to the ICU was 13.8%.
Among 188 COPD patients using HRLDs, the overall mor-
tality rate was 16.5% (31/188).For predicting ICU, hospital, and 30-day mortality rates
after hospital discharge, we included APACHE II score on
admission, age, reasons for ICU admission, NIV and IMV
implications, presence of septic shock, CRP level, and pre-
vious HRLD use in the binary logistic regression model.
The significant predictors and the effects of beta-blocker
use are summarized in Table 4. Beta blocker use was not
found to have a significant effect on mortality rate in the
Table 2 Heart rate limiting drugs in groups
(case: beta-blockers, control: non-beta-blockers)
Case, n = 74 Control, n = 114 p
Previous HRLD use, n (%) 31(41.9) 57 (50.0) 0.28
Previously used HRLDs
Beta-blocker, n (%) 27 (87.1) 4 (7.0) 0.001
Diltiazem, n (%) 1 (1.4) 37 (64.9)
Amiodorone, n (%) 0 (0.0) 2 (3.5)
Digitoxin, n (%) 0 (0.0) 3 (5.3)
Multidrug*, n (%) 3 (12.9) 11 (19.3)
HRLDs used in ICU
HRLD, n Metoprolol = 59 Diltiazem = 91 –
Bisoprolol = 4 Digoxin = 2
Carvedilol = 11 Amiodorone = 3
*More than one =18
Reasons for
HRLD use, n(%)
AF 17 (23.0) 35 (50.7) 0.004
SVT 31 (41.9) 62 (54.4)
VT 0 (0.0) 1 (0.9)
CHF 13 (17.6) 5 (4.4)
HT 6 (8.1) 10 (8.8)
Suspicion of MI 7 (9.5) 1 (0.9)
Only received HRLDs
on day 1, n (%)
4 (5.4) 13 (11.4) 0.16
Intermittent HRLD
use, n (%)
7 (9.5) 11 (9.6) 0.97
♦Heart rate/min on
admission to ICU
111 (21) 115 (25) 0.31
♦Highest heart
rate/min
128 (25) 133 (20) 0.14
♦MAP, mmHg on
admission of ICU
97 (26) 101 (25) 0.33
♦Highest MAP,
mmHg
118 (20) 119 (21) 0.63
*More than one drug used (ie: diltiazem ± digitoxin ± amiadorone). AF, atrial
fibrillation; CHF, congestive heart failure, HRLD, heart-rate limiting drug; HT,
hypertension, ICU, intensive care unit; MAP, mean arterial pressure; MI,
myocardial infarction, SVT, supraventricular tachycardia; VT, ventricular
tachycardia. ♦mean (± standard deviation).
Table 3 ICU outcome data of the two groups
(case: beta-blockers, control: non-beta-blockers)
Outcome Case, n = 74 Control, n = 114 p
Application of NIV, n (%) 67 (90.5) 87 (76.3) 0.013
NIV duration, day 6 (3–7) 5 (2–8) 0.84
Application of IMV, n (%) 25 (33.8) 40 (35.1) 0.85
IMV duration, day,
median (quartile 1–3)
2 (1–5) 5 (2–9) 0.10
Length of ICU stay,
median (quartile 1–3)
6 (4–10) 7 (4–10) 0.69
ICU mortality, % 17.6 15.8 0.75
Hospital mortality, % 18.9 19.3 0.95
30 day mortality, % 20.0 (12/60) 11.0 (10/91) 0.13
ICU, intensive care unit; IMV, Invasive mechanical ventilation, NIV, noninvasive
mechanical ventilation.
Kargin et al. Multidisciplinary Respiratory Medicine 2014, 9:8 Page 6 of 9
http://www.mrmjournal.com/content/9/1/8ICU, the hospital, or within 30 days of discharge. The
presence of septic shock on admission to the ICU and
lower PaO2/FiO2 were found to be significant risk factors
for ICU mortality (Table 4). For hospital mortality, the
presence of septic shock in the ICU, lower PaO2/FiO2, and
HT were found to be associated with increased rate
and conversely NIV application was with decreased
rate (Table 4). The presence of coronary heart diseases
increased the short-term (30 days) mortality risk after
hospital discharge, whereas higher pH levels decreased
the 30-day mortality rate (Table 4).Discussion
The present study showed similar mortality rates and
length of ICU stay in COPD patients with ARF who re-
ceived either beta-blockers or other HRLDs to control
heart rate.
Although the useful effects of beta-blockers in the treat-
ment of cardiac diseases are well-known, their use in
COPD patients has been restricted due to possible contra-
indication [25]. It has been reported that selective and
non-selective beta-blockers increase airway hyperrespon-
siveness (AHR) [9]. In a murine model of antigen-induced
airway inflammation and AHR, acute and chronic treat-
ment with beta-blockers increased and decreased AHR, re-
spectively, but the mechanism of this event has not been
established [26]. However, evidence from trials and meta-
analyses suggests that cardioselective beta1-blockers should
not be routinely withheld from patients with COPD be-
cause the potential benefits outweigh the risks [27]. A
meta-analysis that pooled 22 randomized blinded control
trials of patients with COPD demonstrated that cardiose-
lective beta-blockers, given as a single dose or for longer
durations, produced no significant change in FEV1 or re-
spiratory symptoms [28]. In the present study, the rate of
NIV application was significantly greater in beta-blocker
users than in non-beta-blocker users, and the need of ini-
tial IMV was three times higher in the non-beta-blockers
group, although that was not statistically significant. Not-
ably beta-blocker use did not lead to a worsening in patient
condition in our study.
Cardiovascular diseases (CVDs), including CAD, heart
failure, AF, and HT are major comorbidities in COPD
[7,29,30]. In the present study, AF was found to be the
major comorbidity. Some short-term studies have demon-
strated the safety of using selective beta-blockers in CAD
with COPD [10,31]. Selective beta-blockers (e.g., bisopro-
lol) have a crucial effect on survival in patients with HF,
but the presence of COPD is a common reason for
Case Group: Beta-Blockers Control Group: NonBeta-Blockers
n=74 n=114
O2 alone, n=3 O2 alone, n=9Only IMV, n=4 Only IMV,







































Figure 2 Mechanical ventilation and ICU mortality in study groups.
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present study, the majority of patients were treated with
metoprolol (79.7%), and a few were given bisoprolol (5%).
Dransfield and coworkers reported that the prevalence of
beta-blocker use in COPD patients with either MI or CHF
was 31% [34]. However, there is no clear data regarding
beta-blocker use in the ICU. The present study showed
that beta-blockers were used for similar reasons in 19.4%
of COPD patients. Some studies found that using cardio-
selective beta1-blockers in COPD patients with acute myo-
cardial infarction was safe [10,11]. Conversely, otherTable 4 Logistic regression analysis of mortality risk factors i
ICU mortality risk factors
Odds ratio
Septic shock in the ICU 7.49
PaO2/FiO2 on admission to the ICU 0.99
Beta-blocker use 1.14
Hospital mortality risk factors
Septic shock in the ICU 6.29
Hypertension 2.94
NIV in the ICU 0.21
PaO2/FiO2 on admission to the ICU 0.99
Beta-blocker use 0.98
30 days mortality risk factors
pH on admission to the ICU 0.71
Ischemic cardiac disease 4.77
Beta-blocker use 2.03
FiO2, fractionated inspired oxygen ratio; ICU, intensive care unit; NIV, noninvasive mstudies reported that beta-blockers diminished the beta-
agonist effect [8,9]. Brooks and colleagues studied the
rates of hospitalizations and emergency department (ED)
visits during cardioselective and non-selective beta-
blocker therapy in patients with asthma and/or COPD
[35] and demonstrated the safety of cardioselective beta1-
blockers in patients with COPD. Although the risk of ED
visits was slightly increased, the risk of hospitalization was
reduced. In the same study, non-selective beta-blocker
therapy in COPD patients reduced both the rate of ED
visits and the total number. These findings suggest a largern the ICU, hospital and 30 days after hospital discharge












echanical ventilation; PaO2, partial arterial oxygen pressure.
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http://www.mrmjournal.com/content/9/1/8safety margin with beta-blocker therapy in patients with
COPD compared to those with asthma, with or without
COPD [35]. A recent study demonstrated the safety of
beta-blocker treatment during COPD exacerbation in hos-
pitalized patients with CVD [36]. The present findings also
support the safety of beta-blockers compared with non-
beta-blockers in COPD patients with ARF, due to the
presence of CVD in the ICU.
Confalonieri and coworkers reported that the mortality
rate of COPD patients with ARF in the ICU was 13.7%,
and NIV and IMV failed in 60.2% and 49.2% of patients,
respectively [37]. In this study, the overall mortality rate
was 19.5%, and the mortality rate for COPD patients
was 13.8%. However, the mortality rates for HRLD users,
NIV failure patients, and initial IMV use in COPD pa-
tients were 16.5%, 25.6%, and 40.1%, respectively. Thus,
our results are similar to those of Confalonieri et al. Al-
though Alaithan and co-authors recently described a
mortality rate in COPD patient populations as low as 6%
in the ICU [38], the APACHE II scores were consider-
ably lower than in our study and others.
There are some limitations in our study. Firstly, it was
a retrospective, single-center study. A large, specific
patient group followed by experienced ICU pulmonolo-
gists/intensivists could provide additional important
results. Secondly, spirometry test scores were not re-
corded from the patients’ files. Thirdly, these findings
are relevant to a specific patient population and cannot
be generalized for all patients. The mortality rates of the
groups were very close to each other and although a
reasonable number of patients was included in our
study, the sample size was not large enough to show a
significant difference.
We found that a large number of COPD patient using
HRLDs (either beta-blockers or non-beta-blockers) had
similar outcomes (mortality and length of ICU stay). How-
ever, these patients had a higher rate (16.5%) of mortality
than COPD patients who were not treated with HRLDs in
the ICU (13.8%). The ~33% increase in mortality among
HRLD users can be explained by the primary reason that
these drugs are administered in the ICU. Severe sepsis,
unresponsiveness to treatment, and septic shock were the
main mortality risk factors in our patient population.Conclusions
This study provides a contribution to the controversial
topic of using beta-blockers to limit heart rate in COPD
patients with ARF in the ICU. As with other HRLDs,
beta-blockers are utilizable for patients with bronchocon-
striction due to underlying COPD in the ICU.Competing interest
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